We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TRLS Trellus Health Plc

0.00 (0.0%)
08 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.75 36,627 07:30:58
Bid Price Offer Price High Price Low Price Open Price
3.50 4.00 3.75 3.75 3.75
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors USD 18k USD -8.81M USD -0.0545 -0.69 6.06M
Last Trade Time Trade Type Trade Size Trade Price Currency
13:39:24 O 36,627 3.50 GBX

Trellus Health (TRLS) Latest News

Trellus Health (TRLS) Discussions and Chat

Trellus Health Forums and Chat

Date Time Title Posts
01/12/202312:24Trellus Health - Digital Health Solution for complex chronic conditions294

Add a New Thread

Trellus Health (TRLS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-08 13:39:253.5036,6271,281.95O

Trellus Health (TRLS) Top Chat Posts

Top Posts
Posted at 08/12/2023 08:20 by Trellus Health Daily Update
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 3.75p.
Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £6,056,562.
Trellus Health has a price to earnings ratio (PE ratio) of -0.69.
This morning TRLS shares opened at 3.75p
Posted at 01/12/2023 12:24 by hatfullofsky
TRLS are now trading 40% below their cash level
Posted at 03/10/2023 15:10 by hatfullofsky
I was waiting for the user numbers too and to hear they have moved the 130 [paying] members $100 / month to a free service as part of a community feedback programme really hurt. There is clearly no demand in the D2C model and that's why they pushed the B2B emphasis on the investor call.

If this tool does save money for the payer there is a clear business case. You could see the health care provider making it mandatory for all IBS / IBD sufferers.

But the "potential share of savings" being the "significant upside" worries me when they have no users yet

6,200 members at $1,250 is breakeven £7.75m so current cash levels support the 2025 timeline.

Their current pilot programmes have a TAM of 325 users and we'll only get results in Q2-24.

They alluded to signing a major pilot programme (I guess before year end), that will attract interest and then the results in Q2 but really we are going to be waiting a long time for this to ignite
Posted at 01/9/2023 12:06 by hatfullofsky
Breakeven is on the IMC slide deckAt $100 per patient per month, breakeven at 6200 members (2.5% of TAM)Cash at $19m 2022 v $24m 2021, burn below $700k per month in 2023, cash into 2025 (at current revenue levels and capital investment)In early and late stage discussions with several health plans 2023 expecting revenue take off as 2022 pilot contracts roll into commercial agreements.130 patients currently enrolled (a long way to 6200)TRLS need to announce contracts and enrolment numbers for this to recover
Posted at 25/4/2023 17:23 by idomeneo
This might not be the bottom but I bought £5k here. There are lots of negatives, but there is time and cash (it qualifies as a Ben Graham Net Net which has returned 460% over the last 11 years). They may need a stock market oriented CEO who is prepared to do the things which creates the noise to get people interested, but in the meantime we have a results day plus hopefully an "Investor Meet Company" or similar following that. There was no liquidity for that £5k, so it is just available to private punters at this price. No guarantee at all of a long term win, but that doesn't have to matter. Could tank to 4p if they come with nothing to say.
Posted at 11/4/2023 08:31 by mikemine1
TRLS seems to fit right in there with the Commission's view of the future. Well done Wan.
Posted at 28/2/2023 10:11 by wan
Well, do we assume that the delay of around 6 weeks in launching the D2C IBS offering (still ahead of the originally expected launch for IBS in H1 2023) has had a bearing on the delayed TU?

Not to mention the progression to late-stage discussions with several pharma co.'s and patient services partners who deliver programs to pharmaceutical companies, is perhaps also taking longer, and I can see that some pharma's have an interest in addressing IBS (and IBD e.g. Takeda), and that a certain patient service partner covers IBS, but not IBD.

I am trying to remain somewhat optimistic (but it's wearing thinner by the day) but in any regard, the share price performance since admission to AIM has been utterly uninspiring, and thus the management have a 'lot' to do to change that!
Posted at 24/2/2023 14:47 by wan
Idomeneo...I agree that the CEO is excellent.

Certainly the share price performance appears to be reflecting disappointment, and not reporting as guided is clearly not helping matters. And lets face it, whilst the recent updates have been encouraging, none of them have been game changing, but they should nonetheless contribute positively this year.

The increasing interest from pharmaceutical companies and the progression to late-stage discussions (with at least two), might change the dynamics if they can successfully conclude something material.

Perhaps those discussions are taking longer, and they had hoped to include them as part of the detailed trading update, which in turn would imply they might be close to concluding?

I also have my eye on larger entities in the healthcare space where partnering with Trellus in addressing chronic conditions (initially IBD & IBS), could make a good fit strategically (expanding to address other chronic conditions, and/or some already covered by those entities), especially given that Trellus Health is the first and only digital health company to offer a 'scientifically validated', personalised resilience-based self-management training program for people living with chronic conditions which has been proven to reduce unplanned hospitalizations by 94%.

After the disappointingly slow progress to date though, and the market in a state of being very unforgiving, updates of only incremental progress will hardly be well received given the early stage Trellus is at.
Posted at 24/2/2023 12:34 by idomeneo
"The Company expects to provide a more detailed trading update by early February 2023." It's late February and so far nothing.
CEO was saying on the 3rd October call that she had been "strategically insulated" but there would now be a lot more news flow and evidence of the financial benefits. Since October the best news has been the agreement with New York State-based health
insurer to offer the Trellus IBD program to up to 50 of its members over a
12-month period. So they just need another 7020 more to break even.
As far as I can tell nothing is happening with the b2c with the app which is surely where some money should be coming in. The downloads are negligible, so I don't see what will change to make this increase. In theory they the app is being pushed by the relevant IBD groups, but for whatever reason this is not translating into downloads (and therefore payments). If you are not being "sold" the Trellus System why would you choose it of your own volition?
I'm really scratching my head with this one. The CEO appears competent and dynamic but it would appear that the company will need all the funding it has and more to get this off the ground. After the call I was expecting that before now there would have been at least one announcement in the vein of "we have signed up XYZ Insurance Scheme which covers 3 million people and they will offer it to their 9000 IBD clients" All we have so far is a trial, which doesn't sound like they have been able to sell what they do without the insurer checking it for themselves despite the clinical evidence.

At a launch price of 40p: "The Company expects to generate initial revenue in 2021 through demonstration projects with healthcare payers in the New York City metropolitan area". So what happened to that? Why isn't that generating revenue now? Agreements and understandings mean nothing without a clear indication of the likely imminent revenue.

Has anybody any evidence of better actual financial news? Wouldn't it have been better to have made an announcement explaining why they were delaying the promised early Feb update?
Posted at 13/2/2023 07:55 by wan
With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report -

Significant progress with advancing B2B2C model
I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers.

We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon.

We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform.

Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution

Hopefully we will see continued execution in IBS expansion and the pharma discussions/contracts that were also referred to, not to mention "The Company expects to provide a more detailed trading update by early February 2023."
Posted at 14/12/2021 10:43 by cambridgedon
Thanks Wan.
Seems that the RENX and TRls share prices are suffering at the same time! In one sense they both represent a lot lower risk than at the IPO/launch price but the recent falls have also got many to question what they are really worth. Thoughts?
Trellus Health share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |